SurfLink® by NBMolecules®
- where true osseointegration becomes a reality

Nano Bridging Molecules (NBMolecules®), is a privately held Swiss Medical Device/Life Science Research and Development company, focusing on the development of breakthrough surface treatments for dental and orthopedic implants.

The patented surface treatment SurfLink® allows faster and better integration of implants to living bone also referred to as ‘osseointegration’. This is mainly due to SurfLink®’s biomimicking characteristics.

NBMolecules® SurfLink® technology has been developed over a period of 12 years by a multidisciplinary team from a number of renowned academic institutions including the University of Geneva (‘UniGe’), Ecole Polytechnique Fédérale de Lausanne (‘EPFL’), the University of Zürich and the University of Bern. This collaboration has given rise to a highly sophisticated surface treatment technology which offers a range of benefits not found in any other single surface treatment.

NBMolecules® SurfLink® technology is protected by patents owned by the UniGe and EPFL. According to a license agreement entered into with UniGe and EPFL, the university spin-off company NBMolecules®, established in 2002, owns the worldwide exclusive right to full and unrestricted use, development and exploitation of the technology.

In 2008 NBMolecules® established new laboratories and an office in Canton de Vaud, Switzerland. It currently employs 7 people, has entered into over 65 contracts with research institutions and other external service providers, and continues to grow.

SurfLink® Dental, NBMolecules® first dental implant surface treatment, is produced under the ISO 13485 certification and was granted a CE-mark in May 2011. The product launch of SurfLink® Dental is taking place in 2011.